Literature DB >> 26209473

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

Matthieu F Bastide1, Wassilios G Meissner2, Barbara Picconi3, Stefania Fasano4, Pierre-Olivier Fernagut1, Michael Feyder5, Veronica Francardo6, Cristina Alcacer6, Yunmin Ding7, Riccardo Brambilla4, Gilberto Fisone5, A Jon Stoessl8, Mathieu Bourdenx1, Michel Engeln1, Sylvia Navailles1, Philippe De Deurwaerdère1, Wai Kin D Ko1, Nicola Simola9, Micaela Morelli9, Laurent Groc10, Maria-Cruz Rodriguez11, Eugenia V Gurevich12, Maryka Quik13, Michele Morari14, Manuela Mellone15, Fabrizio Gardoni15, Elisabetta Tronci16, Dominique Guehl1, François Tison2, Alan R Crossman17, Un Jung Kang6, Kathy Steece-Collier18, Susan Fox19, Manolo Carta16, M Angela Cenci6, Erwan Bézard20.   

Abstract

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal models; D1 receptor; Dopamine; Dyskinesia; L-dopa; Parkinson's disease

Mesh:

Substances:

Year:  2015        PMID: 26209473     DOI: 10.1016/j.pneurobio.2015.07.002

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  135 in total

1.  p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.

Authors:  Nicoletta Schintu; Xiaoqun Zhang; Alexandra Alvarsson; Roberta Marongiu; Michael G Kaplitt; Paul Greengard; Per Svenningsson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

Review 2.  Dopaminergic modulation of striatal function and Parkinson's disease.

Authors:  Shenyu Zhai; Weixing Shen; Steven M Graves; D James Surmeier
Journal:  J Neural Transm (Vienna)       Date:  2019-04-01       Impact factor: 3.575

Review 3.  Dopamine and addiction: what have we learned from 40 years of research.

Authors:  Marcello Solinas; Pauline Belujon; Pierre Olivier Fernagut; Mohamed Jaber; Nathalie Thiriet
Journal:  J Neural Transm (Vienna)       Date:  2018-12-19       Impact factor: 3.575

4.  Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.

Authors:  Wei Wei; Shengyuan Ding; Fu-Ming Zhou
Journal:  J Neurophysiol       Date:  2016-12-07       Impact factor: 2.714

5.  Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.

Authors:  Oscar Solís; Jose-Rubén García-Montes; Patricia Garcia-Sanz; Antonio S Herranz; Maria-José Asensio; Gina Kang; Noboru Hiroi; Rosario Moratalla
Journal:  Neurobiol Dis       Date:  2017-03-16       Impact factor: 5.996

Review 6.  Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors:  Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal:  Nat Rev Drug Discov       Date:  2018-09-28       Impact factor: 84.694

Review 7.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 8.  Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia.

Authors:  Annalisa Pinna; Marcello Serra; Micaela Morelli; Nicola Simola
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

Review 9.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

10.  BDNF in the Aged Brain: Translational Implications for Parkinson's Disease.

Authors:  N M Mercado; T J Collier; C E Sortwell; K Steece-Collier
Journal:  Austin Neurol Neurosci       Date:  2017-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.